Versant, NEA help fund eye disease biotech Oyster Point

KalVista Eye Image
Oyster Point wants to differentiate its candidates from other dry eye disease treatments on the market.

New startup biotech Oyster Point Pharmaceuticals came out of stealth today with $22 million led by venture capital firms New Enterprise Associates (NEA) and Versant Ventures.

The California biotech will use the series A funds toward new therapies for dry eye disease, as well as “other diseases of the ocular surface.” This should see the company through to phase 2 tests, it says in a release.

It hopes to add to the growing biopharma research in the area and create a new treatment for the more than 16 million adults with the condition in the U.S. alone.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Currently, two treatments are FDA-approved for dry eye disease: Allergan’s Restasis (cyclosporine ophthalmic emulsion) and Shire’s Xiidra (lifitegrast ophthalmic solution), which both focus mainly on suppressing inflammatory aspects of the disease. Oyster Point’s lead compounds are looking to stimulate natural tear production.

Dry eye disease is characterized by underperforming tear production, as well as inflammation and tissue degradation, and is typically related to age.

A number of other biopharmas are also working on the disease, including Mitotech, Aldeyra and Imprimis/Surface Pharmaceuticals. Mitotech is working on SkQ1, which it hopes will deal with the condition on a cellular level by protecting the eye from oxidative stress.

Aldeyra meanwhile is working on ADX-102, an aldehyde trap focusing on ocular inflammation, which has seen its setbacks; and Surface Pharmaceuticals, which was recently spun out of Imprimis, has a formulation of the steroid betamethasone that it hopes can help dry eye patients.

RELATED: After conjunctivitis flop, Aldeyra plays on positives for dry eye disease

Oyster Point CEO Jeffrey Nau, Ph.D., an Ophthotech and Genentech veteran, said: “Currently marketed products and epidemiological studies have demonstrated the very large market potential for therapies to treat ocular surface diseases, but available prescription and over‐the‐counter therapeutics leave significant unmet need. We are very pleased with Oyster Point’s clinical trial data to date, and there has been major interest from both doctors and patients to have our first‐in‐class products available.”

“We believe Oyster Point’s products have the potential to substantially improve on existing therapies and provide significant benefit to patients,” added Clare Ozawa, Ph.D., a managing director at Versant. “We’re pleased to join with NEA to bring this company to a significant value inflection point.”

Suggested Articles

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.